OBJECTIVES:  To establish whether identification of patients with statin-associated symptoms (SAS), particularly muscle-related symptoms (MRS) in real-world practice is aligned with the latest clinical consensus. METHODS: A web-based survey was conducted in France, Germany, Italy, the Netherlands, Poland, Spain, Sweden, and the UK in February–March 2014. Sixty clinicians per country answered questions about clinical criteria used to identify patients with SAS. These criteria from real-world practice were compared with those recommended in the 2015 European Atherosclerosis Society Consensus Panel Statement (EASCPS) to explore their alignment. RESULTS: Overall, 319 clinicians (76% cardiologists) completed the survey. Almost all clinicians (average 98%; range across countries [RAC] 97–100%) saw and considered MRS in patients receiving statins to indicate SAS. Across countries, an average of 69% of clinicians reported testing for elevated creatine kinase (CK) levels in all patients newly prescribed statins; an average of 52% reported testing in patients who displayed MRS. On average, 77% of clinicians (RAC 68–85%) reported trying ≥2 statins before considering MRS to be SAS; 65% (RAC 57–73%) tried ≥3 statins. Most clinicians (average 74%; RAC 63–85%) reported rechallenging patients with the same statin to confirm whether MRS were SAS. Of those who did not rechallenge, 61% (RAC 50–67%) reported discontinuing the statin to test whether MRS resolved, and an average of 38% (RAC 32–45%) reported using a combination of rechallenging, discontinuing, and lowering the dose of statin to confirm SAS. Of the reported criteria used for determining SAS, CK testing upon MRS and trial of ≤3 statins are consistent with the latest EASCPS, although routine CK testing and statin rechallenge are not fully consistent. CONCLUSIONS: This survey suggests that the clinical criteria used to identify patients with SAS across eight European countries are broadly consistent with the current clinical consensus in Europe.